Drugs / BI 764524
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT04424290 | Jun 2020 → Apr 2023 | diabetic retinopathy | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT06321302 | May 2024 → Mar 2027 expected | diabetic retinopathy | Boehringer Ingelheim | Active not recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BI 764524 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04424290 ↗ |
| Route | Intravitreal | “received one intravitreal injection of low dose BI 764524” NCT04424290 ↗ |
| Target | SEMA3A | “novel mechanism of action (Sema3A modulation)” PMID 35978329 ↗ Aug 2022 |